---
figid: PMC5822899__IJE2018-2637418.002
figtitle: 'Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose
  Tissue'
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC5822899
filename: IJE2018-2637418.002.jpg
figlink: /pmc/articles/PMC5822899/figure/fig2/
number: F2
caption: 'Schematic illustration of the main intracellular pathways underlying WAT
  metabolic functions and the effects of drugs used in dyslipidemia and obesity on
  these pathways: B-oxidation (∗through upregulation of ACS, CD36, MCD, and CPT1 genes
  and after stimulus as PPARα agonist or adrenergic agonists, through upregulation
  of the AMPK pathway); lipolysis (sequentially by ATGL, HSL, and MGL actions); lipogenesis
  (∗through upregulation of GLUT4; ACC genes). Statins induce adipocyte FA uptake,
  increasing LPL expression, while decreasing cholesterol release. ∗Only in obese
  models, statins stimulate lipogenesis de novo; globally, fibrates inhibit lipogenesis
  and stimulate FA oxidation and thermogenesis (∗through upregulation of PRDM16, PPAR-γ,
  and UCP-1 gene expression); niacin inhibits lipolysis and increases lipogenesis
  gene expression; orlistat enhances TG degradation. See text for more details. →:
  stimulates; ⊣: inhibits; TG: triglycerides; FA: fatty acid; Ch: cholesterol; LPL:
  lipoprotein lipase; VLDL: very low-density lipoproteins; DGAT: diacylglycerol acyltransferase;
  ACC: enzyme acetyl-coenzyme A carboxylase; SREBP1: sterol regulatory element-binding
  protein 1; ChREBP: carbohydrate response element-binding protein; GLUT4: glucose
  transporter type 4; PI3-K: phosphoinositide 3-kinase dependent; PDE3B: phosphodiesterase
  3B; AC: adenylyl cyclase; cAMP: cyclic adenosine monophosphate; PKA: cAMP-dependent
  protein kinase A; PKB/Akt: protein kinase B; GC activity: guanylyl cyclase activity;
  cGMP: cyclic guanosine monophosphate; PKG: cGMP-dependent protein kinase; ATGL:
  adipocyte triglyceride lipase; HSL: hormone-sensitive lipase; MGL: monoacylglycerol
  lipase; PPARs: peroxisome proliferator-activated receptors; PGC-1a: peroxisome proliferator-activated
  receptor G coactivator 1; ACS: acyl-CoA synthetase; CD36/FAT: fatty acid translocase;
  CPT1: carnitine palmitoyl transferase 1; AR: adrenoceptors; ANP/BNP: atrial or brain
  natriuretic peptide; NPR-A: natriuretic receptor A; IR: insulin receptor; IRS: insulin
  receptor substrate; AMPK: adenosine monophosphate-activated protein kinase; SIRT1:
  sirtuin 1; BAT: brown adipose tissue; HDLs: high-density lipoproteins; LXRα: liver
  X receptor alpha; ABCA1 transporter: ATP-binding cassette A1 transporter; SRB1:
  scavenger-receptor 1.'
papertitle: 'Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose
  Tissue.'
reftext: Sofia Dias, et al. Int J Endocrinol. 2018;2018:2637418.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.5790193
figid_alias: PMC5822899__F2
figtype: Figure
redirect_from: /figures/PMC5822899__F2
ndex: 9ba5851b-df38-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5822899__IJE2018-2637418.002.html
  '@type': Dataset
  description: 'Schematic illustration of the main intracellular pathways underlying
    WAT metabolic functions and the effects of drugs used in dyslipidemia and obesity
    on these pathways: B-oxidation (∗through upregulation of ACS, CD36, MCD, and CPT1
    genes and after stimulus as PPARα agonist or adrenergic agonists, through upregulation
    of the AMPK pathway); lipolysis (sequentially by ATGL, HSL, and MGL actions);
    lipogenesis (∗through upregulation of GLUT4; ACC genes). Statins induce adipocyte
    FA uptake, increasing LPL expression, while decreasing cholesterol release. ∗Only
    in obese models, statins stimulate lipogenesis de novo; globally, fibrates inhibit
    lipogenesis and stimulate FA oxidation and thermogenesis (∗through upregulation
    of PRDM16, PPAR-γ, and UCP-1 gene expression); niacin inhibits lipolysis and increases
    lipogenesis gene expression; orlistat enhances TG degradation. See text for more
    details. →: stimulates; ⊣: inhibits; TG: triglycerides; FA: fatty acid; Ch: cholesterol;
    LPL: lipoprotein lipase; VLDL: very low-density lipoproteins; DGAT: diacylglycerol
    acyltransferase; ACC: enzyme acetyl-coenzyme A carboxylase; SREBP1: sterol regulatory
    element-binding protein 1; ChREBP: carbohydrate response element-binding protein;
    GLUT4: glucose transporter type 4; PI3-K: phosphoinositide 3-kinase dependent;
    PDE3B: phosphodiesterase 3B; AC: adenylyl cyclase; cAMP: cyclic adenosine monophosphate;
    PKA: cAMP-dependent protein kinase A; PKB/Akt: protein kinase B; GC activity:
    guanylyl cyclase activity; cGMP: cyclic guanosine monophosphate; PKG: cGMP-dependent
    protein kinase; ATGL: adipocyte triglyceride lipase; HSL: hormone-sensitive lipase;
    MGL: monoacylglycerol lipase; PPARs: peroxisome proliferator-activated receptors;
    PGC-1a: peroxisome proliferator-activated receptor G coactivator 1; ACS: acyl-CoA
    synthetase; CD36/FAT: fatty acid translocase; CPT1: carnitine palmitoyl transferase
    1; AR: adrenoceptors; ANP/BNP: atrial or brain natriuretic peptide; NPR-A: natriuretic
    receptor A; IR: insulin receptor; IRS: insulin receptor substrate; AMPK: adenosine
    monophosphate-activated protein kinase; SIRT1: sirtuin 1; BAT: brown adipose tissue;
    HDLs: high-density lipoproteins; LXRα: liver X receptor alpha; ABCA1 transporter:
    ATP-binding cassette A1 transporter; SRB1: scavenger-receptor 1.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - .na.character
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Pka-C1
  - Pka-R2
  - Pka-C3
  - Pka-R1
  - Pka-C2
  - Lamp1
  - ATPsynbeta
  - Atpalpha
  - ac
  - kni
  - 18w
  - tok
  - tlr-2
  - AdipoR
  - Erk7
  - rl
  - Nplp1
  - egr
  - par
  - para
  - par-6
  - sta
  - Inos
  - Nos
  - kn
  - Oli
  - SNF4Agamma
  - AMPKalpha
  - Stat92E
  - EDN1
  - CALM1
  - VCAM1
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - CCL2
  - CX3CL1
  - CEBPA
  - CEBPB
  - CEBPD
  - CEBPG
  - CEBPE
  - LSAMP
  - LAMP3
  - ATP8A2
  - ADCY1
  - ADCY2
  - ADCY3
  - ADCY4
  - ADCY5
  - ADCY6
  - ADCY7
  - ADCY8
  - ADCY9
  - ADCY10
  - CD40LG
  - NAMPT
  - IL6
  - TLR1
  - TLR2
  - TLR3
  - TLR4
  - TLR5
  - TLR6
  - TLR7
  - TLR8
  - TLR9
  - TLR10
  - EPHB2
  - MAPK1
  - MAPK3
  - TNF
  - NR1I2
  - JTB
  - EMD
  - GCY
  - IL12A
  - IL12B
  - TOE1
  - NOS2
  - ISYNA1
  - MYO1G
  - CD40
  - PPARA
  - PPARD
  - PPARG
  - RXRA
  - IGKV2-40
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - IFNG
  - Statins
  - Cortisol
  - Niacin
  - Sbutramine
  - Ssibutamine
  - 'N'
  - Sibutramine
---
